Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 6 clinical trials
Study to Assess the Safety, Pharmacokinetics, and Efficacy of KPL-404 in Participants With Rheumatoid Arthritis With Inadequate Response or Intolerance to at Least One Biologic Disease-modifying Anti-rheumatic Drug or a Janus Kinase Inhibitor

Phase 2 study of the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and efficacy of KPL-404 in subjects with moderate to severe Rheumatoid Arthritis.

abatacept
infliximab
rituximab
antirheumatics
sulfasalazine
  • 0 views
  • 22 Apr, 2022
  • 8 locations
Assessing An Oral Janus Kinase Inhibitor, AZD4205 as Monotherapy in Patients Who Have PTCL (JACKPOT8)

This is a multinational, non-randomized, open-label, Phase 1/2 clinical study to evaluate the safety, tolerability and anti-tumor efficacy of AZD4205 as monotherapy in patients with peripheral T cell lymphoma (PTCL), who have relapsed from or are refractory/intolerant to standard systemic treatment. Phase 1 part: Around 20~40 patients will be subsequently …

systemic therapy
t-cell lymphoma
measurable disease
peripheral t-cell lymphoma
  • 6 views
  • 25 Mar, 2022
  • 44 locations
Safety of Tofacitinib, an Oral Janus Kinase Inhibitor, in Primary Sjogren's Syndrome

Background An autoimmune disease is one in which the immune system attacks a person s own body. Sjogren's syndrome (SS) is an autoimmune disease. It often involves multiple systems and organs of the body. Researchers are trying to find new, more effective and safe treatments for SS. Objective To evaluate …

chloroquine
glucocorticoids
tofacitinib
hydroxychloroquine
autoimmune disease
  • 0 views
  • 11 May, 2022
  • 1 location
Study of Itacitinib for the Prophylaxis of Graft-Versus-Host Disease and Cytokine Release Syndrome After T-cell Replete Haploidentical Peripheral Blood Hematopoietic Cell Transplantation

In this trial, the investigators will begin to explore the possibility that, as in mice, janus kinase inhibitor 1 (JAK1) inhibition with haploidentical-hematopoietic cell transplantation (HCT

hodgkin's disease
blast cells
bone marrow transplant
leukemia
mycophenolate mofetil
  • 0 views
  • 01 Mar, 2022
  • 1 location
Evaluate the Efficacy and Safety of Topical SHR0302 Ointment in Patients With Mild-to-Moderate Atopic Dermatitis

This is a Randomized, Double-blind, Vehicle-Controlled, Seamless and Adaptive-designed Phase II/III Study to Evaluate the Efficacy and Safety of Topical SHR0302 Ointment in Adult and Adolescent Patients with Mild-to-Moderate Atopic Dermatitis. It will consist of phase II and phase III parts, phase II will be a dose-ranging part and phase …

  • 0 views
  • 29 Jan, 2021
  • 21 locations
Korean Post-marketing Surveillance for Xeljanz XR (XRPMS)

Xeljanz(tofacitinib) is a potent, oral janus kinase inhibitor. Xeljanz Tab 5mg was approved by MFDS in 2014 for the treatment of adult patients with moderately to severely active rheumatoid

  • 0 views
  • 13 May, 2022
  • 1 location